Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naïve extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901

Naoto Morikawa, Akira Inoue, Shunichi Sugawara, Makoto Maemondo, Toshiyuki Harada, Masao Harada, Yuka Fujita, Terufumi Katoh, Hiroshi Yokouchi, Hiroshi Watanabe, Kazuhiro Usui, Toshiro Suzuki, Jun Sakakibara-Konishi, Hiroki Nagai, Mariko Kanbe, Toshihiro Nukiwa

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naïve extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science